Wallis R B
Thromb Res Suppl. 1983;4:31-8. doi: 10.1016/0049-3848(83)90355-9.
Sulphinpyrazone normalises the shortened platelet survival associated with gout or artificial heart valves and has shown benefit in secondary prevention of myocardial infarction. The compound is metabolised in all species but in variable amounts to a sulphide metabolite which is a potent cyclo-oxygenase inhibitor. At the plasma concentration found in man, the metabolic inhibits prostaglandin synthesis-dependent platelet behaviour and this is therefore the likely mechanism of action of sulphinpyrazone. The compound has some additional effects which may be important.
磺吡酮可使与痛风或人工心脏瓣膜相关的缩短的血小板生存期恢复正常，并已显示出对心肌梗死二级预防有益。该化合物在所有物种中均会代谢，但代谢量各不相同，会生成一种硫化物代谢产物，它是一种强效环氧化酶抑制剂。在人体中发现的血浆浓度下，这种代谢产物会抑制依赖前列腺素合成的血小板行为，因此这可能是磺吡酮的作用机制。该化合物还有一些其他可能很重要的作用。
